Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 0.79 |
| ▸ | RAB9A | P51151 | 9/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | POLB | P06746 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.78 |
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.67 |
| ▸ | BRAF | P15056 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090787 | 0.90 | ALOX12 (0.82) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL17223785 | 0.89 | ALOX12 (0.81) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL609251 | 0.89 | ALOX12 (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL17223781 | 0.88 | KDM4E (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL2598255 | 0.87 | ALOX12 (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL2598272 | 0.87 | ALOX12 (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL2599361 | 0.85 | ALOX12 (0.74) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL610979 | 0.85 | HSP90AA1 (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL1811300 | 0.84 | NPC1 (1.00) | ALOX12NPC1RAB9AKDM4ELMNA | |
| SCHEMBL27790138 | 0.84 | NPC1 (0.80) | ALOX12NPC1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137079-A1 | INHIBITORS OF JMJD2C AS ANTICANCER AGENTS | The J. David Gladstone Institutes (US) | 2017-03-08 | — | — | EP | claimed |
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | THE J. DAVID GLADSTONE INSTITUTES | 2017-02-16 | — | — | US | claimed |
| WO-2015167874-A1 | INHIBITORS OF JMJD2C AS ANTICANCER AGENTS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-11-05 | — | — | WO | claimed |
| US-20130096159-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | The United States of America, as represented the Secretary Department of Health & Human Service (US) | 2013-04-18 | — | — | US | claimed |
| EP-2571853-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146618-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-24 | — | — | WO | claimed |
| CN-101611009-A | Quinoline derivatives | CHRONOGEN INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2079699-A1 | QUINOLINE DERIVATIVES | Envivo Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| WO-2008014602-A1 | QUINOLINE DERIVATIVES | ENVIVO PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| US-20130096159-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | The United States of America, as represented the Secretary Department of Health & Human Service (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2571853-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146618-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-101611009-A | Quinoline derivatives | CHRONOGEN INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2079699-A1 | QUINOLINE DERIVATIVES | Envivo Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008014602-A1 | QUINOLINE DERIVATIVES | ENVIVO PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044107-A1 | Inhibitors of JMJD2C as Anticancer Agents | KDM2A, KDM1B, KDM5C | ALOX12 3591/4885NPC1 3394/4885RAB9A 2430/4885 |
| US-20130096159-A1 | INHIBITORS OF HUMAN 12-LIPOXYGENASE | ALOX12, ALOX15B, ALOX15 | ALOX12 1/4885NPC1 2330/4885RAB9A 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.